Treatment of catecholaminergic polymorphic ventricular tachycardia consists of limitation of moderate and high-intensity effort and administration of high-dose beta blocker drugs (propranolol, nadolol).
Diagnosis and treatment of catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm 2007; 4: 675-8.
Clinical management of catecholaminergic polymorphic ventricular tachycardia: the role of left cardiac sympathetic denervation.
Laver et al., "Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans," Nature Medicine, vol.
Ruan et al., "Short communication: flecainide exerts an antiarrhythmic effect in a mouse model of catecholaminergic polymorphic ventricular tachycardia by increasing the threshold for triggered activity," Circulation Research, vol.
Vanninen et al., "Antiarrhythmic effects of dantrolene in patients with catecholaminergic polymorphic ventricular tachycardia and replication of the responses using iPSC models," PLoS One, vol.
Memmi et al., "Arrhythmogenesis in
catecholaminergic polymorphic ventricular tachycardia: insights from a RyR2 R4496C knock-in mouse model," Circulation Research, vol.
Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia. Circulation 2001;103:196-200.
Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation 2002;106:69-74.
Absence of calsequestrin 2 causes severe forms of catecholaminergic polymorphic ventricular tachycardia. Circ Res 2002;91:21-6.
Knollmann, "Mechanism underlying
catecholaminergic polymorphic ventricular tachycardia and approaches to therapy," Journal of Electrocardiology, vol.